1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/29159
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWilliamson G.en
dc.contributor.authorKerimi A.en
dc.date.accessioned2021-05-14T09:50:33Zen
dc.date.available2021-05-14T09:50:33Zen
dc.date.copyright2020en
dc.date.created20200713en
dc.date.issued2020-07-13en
dc.identifier.citationBiochemical Pharmacology. 178 (no pagination), 2020. Article Number: 114123. Date of Publication: August 2020.en
dc.identifier.issn0006-2952en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/29159en
dc.description.abstractCommonly used drugs for treating many conditions are either natural products or derivatives. In silico modelling has identified several natural products including quercetin as potential highly effective disruptors of the initial infection process involving binding to the interface between the SARS-CoV-2 (Covid-19) Viral Spike Protein and the epithelial cell Angiotensin Converting Enzyme-2 (ACE2) protein. Here we argue that the oral route of administration of quercetin is unlikely to be effective in clinical trials owing to biotransformation during digestion, absorption and metabolism, but suggest that agents could be administered directly by alternative routes such as a nasal or throat spray.Copyright © 2020 Elsevier Inc.en
dc.languageEnglishen
dc.languageenen
dc.publisherElsevier Inc. (E-mail: usjcs@elsevier.com)en
dc.relation.ispartofBiochemical Pharmacologyen
dc.subject.meshdrug bioavailability-
dc.subject.meshdrug dose-
dc.subject.meshdrug metabolism-
dc.subject.meshdrug transformation-
dc.subject.meshSevere acute respiratory syndrome coronavirus 2-
dc.subject.meshangiotensin converting enzyme 2-
dc.subject.meshquercetin/ct-
dc.subject.meshquercetin [Oral Drug Administration]-
dc.subject.meshquercetin-
dc.subject.meshvirus spike protein-
dc.subject.meshprotein protein interaction-
dc.subject.meshcoronavirus disease 2019-
dc.subject.meshdrug absorption-
dc.titleTesting of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction.en
dc.typeReviewen
dc.identifier.affiliationMonash University - School of Clinical Sciences at Monash Health-
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.bcp.2020.114123-
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid32593613 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32593613]en
dc.identifier.source2006930432en
dc.identifier.institution(Williamson, Kerimi) Department of Nutrition, Dietetics and Food, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, BASE Facility, 264 Ferntree Gully Road, Notting Hill, VIC 3168, Australiaen
dc.description.addressG. Williamson, Department of Nutrition, Dietetics and Food, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, BASE Facility, 264 Ferntree Gully Road, Notting Hill, VIC 3168, Australia. E-mail: gary.williamson1@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2020 Elsevier B.V., All rights reserved.en
dc.identifier.authoremailWilliamson G.; gary.williamson1@monash.eduen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeReview-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
Appears in Collections:Articles
Show simple item record

Page view(s)

6
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.